INCY Stock Analysis — Incyte Corporation
Sector: Healthcare
AI Verdict
INCY trades at 11.8x next year's earnings with 17.3% growth expected, making it cheap for the growth you're getting if its drug pipeline continues to deliver.
Competitive Moat
Incyte specializes in proprietary small-molecule drugs for oncology and rare diseases, with flagship products like Jakafi benefiting from long patent protection and entrenched physician adoption. Its pipeline and expertise in targeted therapies create high barriers for generic competition.
Summary
Incyte's forward P/E of 11.8x with 17.3% expected EPS growth makes it a standout among mid-cap biotechs.
Where It Stands
With a 1-year return of 45.12%, a cooling RSI of 45.0, and a forward P/E of 11.8x versus the healthcare median of 22x, the stock looks cheap for its growth profile.
Key Metrics
- RSI: 45 — Neutral
- Trailing P/E: 13.8x
- Forward P/E: 11.8x
- PEG Ratio: 1.21
- Earnings Growth: +0.2%
- Revenue Growth: +0.2%
- Market Cap: $19.3B
- 1-Year Return: 45.12%
- 52-Week High: $112.29
- 52-Week Low: $63.93
Analyst Consensus
16 Buy · 18 Hold · 1 Sell (35 analysts)
Bull Case
Analysts expect 17.3% EPS growth next year while you’re only paying 11.8x forward earnings, a rare combination in this sector.
Bear Case
If the P/E multiple reverts to the sector median of 22x, upside is limited, but if sentiment sours and it drops to 10x, shares could lose roughly 15%.
Catalyst to Watch
Upcoming clinical trial readouts or FDA decisions on pipeline drugs could quickly change growth expectations.